Form 4: Kiniksa Pharmaceuticals Director Barry Quart Reports Significant Equity Grants and Share Acquisition

Kiniksa Pharmaceuticals International, plc Director Barry D. Quart has reported the acquisition of 3,173 Class A Ordinary Shares through the vesting of Restricted Share Units, alongside new grants of 16,798 share options and 2,799 Restricted Share Units.

Summary

• Barry D. Quart, a Director of Kiniksa Pharmaceuticals International, plc (KNSA), reported changes in his beneficial ownership of the company's securities.
• On June 5, 2025, Mr. Quart acquired 3,173 Class A Ordinary Shares as a result of the vesting of Restricted Share Units (RSUs).
• Following this transaction, Mr. Quart directly beneficially owns 12,546 Class A Ordinary Shares.
• On June 3, 2025, Mr. Quart was granted 16,798 share options with an exercise price of $29.11, expiring on June 2, 2035.
• These share options will vest in twelve substantially equal monthly installments following the grant date.
• Additionally, on June 3, 2025, Mr. Quart was granted 2,799 Restricted Share Units (RSUs), which will vest in their entirety on the earlier of the anniversary of the grant date or the date of the Issuer's annual meeting in the following year.

Sentiment

Score: 6

Explanation: The filing indicates routine equity compensation for a director, aligning their interests with shareholders through new grants and the vesting of existing awards. This is generally a neutral to slightly positive event as it reflects ongoing commitment and a standard compensation structure, without indicating any unusual or concerning activity.

Positives

• The acquisition of shares through RSU vesting and the grant of new share options and RSUs increase Director Barry D. Quart's equity stake in Kiniksa Pharmaceuticals, further aligning his interests with those of shareholders.
• The new equity grants serve as long-term incentives for the director, potentially motivating sustained performance and value creation for the company.

Future Outlook

The document outlines future vesting schedules for the newly granted share options and Restricted Share Units. The share options will vest in twelve substantially equal monthly installments, while the 2,799 RSUs will vest in their entirety on the earlier of the anniversary of the grant date or the date of the Issuer's annual meeting in the following year. This indicates future increases in the director's direct share ownership upon full vesting.

Industry Context

This Form 4 filing details routine equity compensation for a director of Kiniksa Pharmaceuticals, a common practice across publicly traded companies in all industries, including the biotechnology and pharmaceutical sectors. Such compensation structures are designed to align the interests of executives and board members with those of shareholders.

Related Party Transactions

• The reported transactions involve equity compensation grants and vesting events for Barry D. Quart, a Director of Kiniksa Pharmaceuticals. These are considered related party transactions as they involve an insider of the company.

Stakeholder Impact

• Shareholders: The transactions increase the director's equity ownership and future incentives, potentially strengthening the alignment of management interests with shareholder value creation.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The 16,798 share options granted on June 3, 2025, will vest and become exercisable in twelve substantially equal monthly installments.
• The 2,799 Restricted Share Units granted on June 3, 2025, will vest in their entirety on the earlier of the anniversary of the grant date or the date of the Issuer's annual meeting in the following year.

Key Dates

Recommendation

Keywords

Kiniksa Pharmaceuticals, KNSA, SEC Form 4, insider transaction, Barry D. Quart, director, equity compensation, share options, restricted share units, beneficial ownership